Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The treatment of migraine is often complicated by insufficient headache relief, a miscellany of side effects and the risk of developing Medication Overuse Headache (MOH). Novel acute therapies have been recently developed and are now in the early post-marketing phase. Lasmiditan is a highly selective serotonin receptor agonist that binds to the 5-HT receptor, while ubrogepant and rimegepant antagonize the calcitonin gene-related peptide receptor. All three medications are now prescribed in a real-world setting, and an adequate level of knowledge is the starting point for rational use. In this rapid systematic review, we have established what is known about lasmiditan, ubrogepant and rimegepant, highlighting the most relevant safety aspects available from published studies and speculating about their risk of MOH.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627250 | PMC |
| http://dx.doi.org/10.2147/DHPS.S304373 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of Availability of Antibiotics for Online Sale and Comparison of E-pharmacies in India.
Cureus
August 2025
Pharmacology, Government Medical College, Patiala, IND.
Introduction The global rise in antimicrobial resistance (AMR) poses a serious public health threat, reducing the effectiveness of commonly used antibiotics against prevalent bacterial infections. The mushrooming of Indian e-pharmacies, especially during and after the COVID-19 pandemic, has improved public access to medicines, including antibiotics. However, the ease of availability, combined with an ambiguous regulatory framework governing e-pharmacies, may inadvertently encourage the irrational use of antibiotics.
View Article and Find Full Text PDFSteps to manage treatment-refractory migraine in adults.
Expert Rev Neurother
September 2025
Department of Neurology, Tallaght University Hospital (TUH)/The Adelaide and Meath Hospital incorporating the National Children's Hospital (AMNCH), Dublin, Ireland.
Introduction: Refractory migraine (RM) is characterized by a lack of response to both migraine-specific and repurposed treatments, significantly impairing quality of life. Risk factors for RM include, among others, overuse of symptomatic medications, nonadherence to treatment and comorbid conditions that limit the use of anti-migraine medications.
Areas Covered: This critical perspective addresses the diagnosis and management of patients with RM.
Loneliness and analgesic overuse among low-dose estrogen-progestin users in Japan.
BMC Womens Health
September 2025
1Division of Social Pharmacy, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105- 8512, Japan.
Purpose: Loneliness is related to menstrual disorders and medication use. Loneliness and pain are related and may be associated with analgesic use. The aim of this study was to investigate the prevalence of concomitant analgesic use and overuse, and to clarify factors associated with loneliness and analgesic overuse among women who are low-dose estrogen-progestin (LEP) users.
View Article and Find Full Text PDFA nomogram for the prediction of response to anti-CGRP mAbs: the CGRP score.
J Headache Pain
September 2025
Digital and Predictive Medicine, Pharmacology, Clinical Metabolic Toxicology-Headache Center and Drug Abuse, AOU Policlinico di Modena, Modena, Italy.
Introduction: Real-world studies have explored potential predictors of response to anti-calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs), though results have remained inconsistent. Machine learning (ML) algorithms are becoming increasingly relevant in migraine research, offering a data-driven approach to identifying predictors of response to preventive treatments. To maximize their potential, a clinically applicable and user-oriented framework is needed to promote the use of these algorithms in research and, eventually, as supportive tools in clinical practice.
View Article and Find Full Text PDFFremanezumab for the treatment of migraine.
Pain Manag
September 2025
Department for Neurology, University Clinical Centre of Nis, Nis, Serbia.
Fremanezumab is a monoclonal antibody inhibiting the CGRP signaling leading to migraine prophylaxis. Its efficacy and potential safety concerns are updated here. All available data on fremanezumab were searched in PubMed with emphasis on the mechanisms of action, efficacy, tolerability, and safety.
View Article and Find Full Text PDF